Wills Financial Group LLC Lowers Position in Merck & Co., Inc. $MRK

Key Points

• Wills Financial Group LLC cut its Merck stake by 48% in the fourth quarter, selling 15,665 shares and ending with 16,955 shares worth about $1.785 million.
• Merck and Gilead reported positive Phase 3 results for their once-weekly HIV regimen islatravir/lenacapavir, bringing the program closer to regulatory filings and a possible new growth driver.
• Not all pipeline news was positive: Merck and Gilead discontinued a Phase 3 lung cancer study after it failed to show a statistically significant benefit, removing a potential oncology catalyst.

Wills Financial Group LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 48.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 16,955 shares of the company's stock after selling 15,665 shares during the period. Wills Financial Group LLC's holdings in Merck & Co., Inc. were worth $1,785,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of MRK. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $25,000. High Note Wealth LLC increased its stake in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after purchasing an additional 109 shares during the period. Tucker Asset Management LLC acquired a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $34,000. Entrust Financial LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $37,000. Finally, United Financial Planning Group LLC purchased a new position in shares of Merck & Co., Inc. in the 3rd quarter valued at about $31,000. Institutional investors and hedge funds own 76.07% of the company's stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Gilead reported positive Phase 3 results for their once-weekly HIV regimen islatravir/lenacapavir, meeting the primary efficacy endpoint in both studies and moving the program closer to regulatory filings. Article: Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
• Positive Sentiment: The HIV data could strengthen Merck’s long-term pipeline and add a potential new growth driver if the once-weekly treatment wins approval and commercialization proceeds as expected. Article: Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
• Neutral Sentiment: Merck also presented at the Goldman Sachs 47th Annual Global Healthcare Conference, which typically reinforces management’s strategy and pipeline commentary but does not by itself change fundamentals. Article: Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Merck’s collaboration with The Hashgraph Group on an EU digital product passport for regulated supply chains is strategically interesting, but it is unlikely to have a near-term material impact on earnings. Article: The Hashgraph Group and Merck Introduce EU Digital Product Passport on Hedera for Regulated Supply Chains
• Negative Sentiment: Merck and Gilead discontinued a Phase 3 non-small cell lung cancer study after it failed to show a statistically significant benefit, which removes one potential oncology catalyst and highlights clinical risk in the pipeline. Article: Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
• Negative Sentiment: Reuters also reported Merck is exploring treatment options for a rare Ebola strain, which may reflect additional research effort but could carry uncertainty around development timing and commercial value. Article: Merck (MRK) Explores Treatment Options for Rare Ebola Strain, Reuters Reports

Merck & Co., Inc. Trading Up 0.0%

MRK opened at $119.54 on Wednesday. The firm has a market cap of $295.24 billion, a price-to-earnings ratio of 33.67, a price-to-earnings-growth ratio of 2.69 and a beta of 0.21. Merck & Co., Inc. has a 52 week low of $76.66 and a 52 week high of $125.14. The business's 50 day moving average is $116.56 and its two-hundred day moving average is $112.85. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company's revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts predict that Merck & Co., Inc. will post 5.17 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be paid a dividend of $0.85 per share. The ex-dividend date is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.8%. Merck & Co., Inc.'s dividend payout ratio is currently 95.77%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. JPMorgan Chase & Co. lifted their price target on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an "overweight" rating in a report on Monday, April 6th. UBS Group increased their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a research note on Monday, April 13th. Barclays began coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They set an "overweight" rating and a $140.00 price objective on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $150.00 target price for the company in a report on Friday, February 13th. Finally, Citigroup began coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They issued a "neutral" rating and a $125.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $128.18.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.